Clinical Research Directory

\[Inclusion Criteria\] 1. Age ≥19 years. 2. Written informed consent obtained before randomization and before any study-specific procedures. The conditions allowing consent before or after PCI follow the footnote of the Schedule of Assessments. 3. Presenting with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS, including unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction), and clinically stable after PCI. 4. Has an indication for coronary PCI based on symptoms, objective ischemia, ACS clinical presentation, coronary physiology, or angiographic findings per routine practice. 5. All treated lesions were treated with the Pantera Lux DCB only and Successful DCB-only PCI in all treated lesions, with visually estimated residual diameter stenosis ≤30%, TIMI grade 3 flow, and no flow-limiting dissection, persistent ischemia, or unresolved major procedural complications. 6. No coronary stent or scaffold was implanted during the index procedure. 7. Able and willing to comply with the assigned antiplatelet regimen and scheduled follow-up, and judged by the investigator to be clinically acceptable for both the 1-month and 6-month DAPT strategies using the P2Y12 inhibitor selected by the investigator. \[Exclusion Criteria\] 1. Unable or unwilling to provide written informed consent. 2. Known contraindication, hypersensitivity, or clinically unacceptable intolerance to aspirin, any P2Y12 inhibitor permitted by the protocol, heparin, paclitaxel, DCB excipients, or iodinated contrast media that cannot be adequately controlled. 3. Active major bleeding at the time of randomization, or another condition that precludes DAPT. 4. Requires, or is expected to require, oral anticoagulation after randomization; or has a separate clinical indication, independent of study assignment, that necessitates DAPT beyond 1 month or makes it impossible to maintain 6-month DAPT, such that one of the two assigned strategies would be inappropriate. 5. Cardiogenic shock, persistent hemodynamic instability, or need for mechanical circulatory support at randomization. 6. Bailout or planned coronary stent/scaffold implantation during the index procedure. 7. Additional PCI (including DCB-only PCI) or CABG planned within the first 6 months after randomization. 8. Coronary stent implantation within 6 months before randomization. 9. History of definite or probable stent thrombosis. 10. In-stent restenosis or stent thrombosis as the study target lesion. 11. Prior coronary artery bypass grafting (CABG). 12. Life expectancy \<1 year due to comorbid conditions. 13. Currently participating in another interventional study that may interfere with treatment or endpoint ascertainment. 14. Pregnant or breastfeeding, or planning pregnancy during the assigned DAPT period. 15. Any other condition in which, in the investigator's judgment, study participation is unsafe or reliable follow-up is unlikely.